Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
iStock / MAYA
Nearly 900 veterinary students and leaders from three dozen veterinary schools across the United States came together virtually this week for the annual National Veterinary Scholars Symposium. They learned from researchers, public health officials, and industry experts about the global burden of disease, infectious disease control, and potential avenues for careers in research – such as emerging and cross-border diseases – where their veterinary training and one-health Perspective are crucial.
In addition, several students received the Boehringer Ingelheim Research Award for Graduate Veterinarians and Veterinary Students. The winning students receive cash prizes and a scholarship to attend the symposium to receive their awards and present their research.
Dr. Brittany Szafran of Mississippi State College of Veterinary Medicine received the Boehringer Ingelheim Veterinary Research Award for Graduate Veterinarians in 2021, promoting research in veterinary life sciences. Qualified veterinarians who have completed or are about to complete a doctoral degree or who have completed their specialist training in veterinary pathology, medicine, surgery, radiology / imaging or laboratory veterinary medicine are recognized. Dr. Szafran’s work focused on the underlying biochemical and immunological mechanisms in response to pesticides in order to better understand and protect human, animal and environmental health from the potential toxicity of chemicals.
Carley Allen of the University of Missouri’s College of Veterinary Medicine received the Boehringer Ingelheim Veterinary Research Award 2021 for veterinary students. Allen’s research focused on investigating a novel molecular target to inhibit cell growth and improve survival in canine osteosarcoma, the most common canine skeletal malignancy, and a beneficial comparative and translational model for human osteosarcoma.
Brittany Allen of the College of Veterinary Medicine at Ohio State University and Jaqueline Chevalier of the College of Veterinary Medicine at Cornell University also received Honorable Mention as Boehringer Ingelheim Veterinary Research Scholars.
The annual National Veterinary Scholars Symposium this year was hosted by the College of Veterinary Medicine at Iowa State University and sponsored by Boehringer Ingelheim, the American Association of Veterinary Medical Colleges, the American Veterinary Medical Association, and the National Institutes of Health. The symposium introduces the research carried out by veterinary medicine students as part of their research internship in the Veterinary Scholar Program.
“These students are entering the life sciences at a remarkable time. The frequency of pandemics and cross-border threats is expected to increase, which poses new and greater risks to human and animal health and to our food supply, ”said Caroline Belmont, Head of US Animal Health Innovation at Boehringer Ingelheim, in a welcoming address to attendees. “The one-health perspective and skills of today’s veterinary students will undoubtedly play a critical role in addressing our future challenges, and the hands-on experience, guidance and support we now offer them represent an important investment in the future health of Animals and humans. “
The Boehringer Ingelheim Veterinary Scholars Program was founded more than 30 years ago to introduce first and second year veterinarians to biomedical research. At each participating school, the Boehringer Ingelheim Veterinary Scholars are assigned a mentor and a laboratory. Every scientist carries out a hypothesis-driven research project. The research project is usually carried out over a period of 10-12 weeks in the summer, with the students presenting their work at the end. Almost 5,000 students have received research grants from Boehringer Ingelheim since the program began. Further information is available at http://veterinaryscholars.boehringer-ingelheim.com/.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, so are people. Our 9,700 employees worldwide are committed to creating value through innovation and thus increasing the well-being of both.
The respect for animals, people and the environment guides us every day. We develop solutions and offer services to protect animals from disease and pain. We support our customers in caring for the health of their animals and protect our communities from life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the world’s second largest animal health company with net sales of $ 4.7 billion in 2020 and a presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a strong presence in the USA with more than 3,100 employees in Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico, among others. To find out more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
The manufacture of new and better drugs for humans and animals is the focus of our actions. Our mission is to create breakthrough therapies that change lives. Boehringer Ingelheim has been independent and family-owned since it was founded in 1885. We have the freedom to pursue our long-term vision, anticipate future health challenges, and focus on the areas where we can do best.
As the world’s leading, research-oriented pharmaceutical company with around 52,000 employees, we create value every day through innovation for our three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
In 2020 Boehringer Ingelheim achieved net sales of around 22.33 billion US dollars (19.57 billion euros). Our significant investment of over $ 4.2 billion (€ 3.7 billion) in 2020 (18.9% of net sales) in research and development drives innovation and enables the next generation of life-saving medicines Improve quality of life.
We’re realizing more science opportunities by harnessing the power of partnership and the diversity of experts across the life science community. By working together, we are accelerating the achievement of the next medical breakthrough that will change the lives of patients now and for generations to come.